[Roncoleukin immunomodulation in pulmonary tuberculosis].

Area of Science:

• Immunology
• Pulmonology
• Medical Microbiology

Background:

• Pulmonary tuberculosis remains a significant global health challenge.
• Severe, progressive forms of tuberculosis often require adjunctive therapies.
• Immunomodulation is a potential strategy to enhance treatment efficacy.

Purpose of the Study:

• To evaluate the clinical and immunological effects of roncoleukine (recombinant human interleukin-2) in patients with severe pulmonary tuberculosis.
• To assess the safety and efficacy of roncoleukine as an immunomodulator in this patient group.

Main Methods:

• A study involving 25 patients with fibrocavernous pulmonary tuberculosis undergoing therapy.
• Administration of roncoleukine to assess clinical outcomes and immunological parameter changes.
• Monitoring for complications associated with roncoleukine treatment.

Main Results:

• Roncoleukine demonstrated a clinical efficacy rate of 80.8% in the treated patients.
• No significant complications were reported during roncoleukine administration.
• Immunological parameters showed a trend towards normalization, with a notable increase in baseline cellular immunity.

Conclusions:

• Roncoleukine is a safe and effective immunomodulator for treating severe pulmonary tuberculosis.
• The observed improvements in clinical and immunological parameters support its use in managing complex tuberculosis cases.